COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,757 Articles (22,502 medRxiv, 8,255 bioRxiv)

Most recent first Previous |  Page 1106: Articles 11051-11060  | Next

Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants
Di Germanio, C., Simmons, G., Thorbrogger, C., Martinelli, R., Stone, M., Gniadek, T., Busch, M. P.
10.1101/2021.10.28.21265622 — Posted: 2021-10-30
COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity
Shen, Y., Freeman, J. A., Holland, J., Solterbeck, A., Naidu, K., Soosapilla, A., Downe, P., Tang, C., Kerridge, I., Wallman, L., Van Bilsen, N., Milogiannakis, V., Akerman, A., Martins Costa Gomes, G., Sandgren, K., Cunningham, A. L., Turville, S., Mulligan, S. P.
10.1101/2021.10.28.21265549 — Posted: 2021-10-30
An Objective Search for Unrecognized Bias in Validated COVID-19 Prediction Models
Estiri, H., Strasser, Z., Rashidian, S., Klann, J., Wagholikar, K., McCoy, T., Murphy, S.
10.1101/2021.10.28.21265629 — Posted: 2021-10-30
Correlates of COVID-19 Vaccine Hesitancy among People who Inject Drugs in the San Diego-Tijuana Border Region
Strathdee, S. A., Abramovitz, D., Harvey-Vera, A. Y., Vera, C., Rangel, G., Artamonova, I., Patterson, T. L., Mitchell, R., Bazzi, A. R.
10.1101/2021.10.29.21265669 — Posted: 2021-10-30
Trends in SARS-CoV-2 seroprevalence in Massachusetts estimated from newborn screening specimens
Ma, K. C., Hale, J. E., Grad, Y., Alter, G., Luzuriaga, K., Eaton, R. B., Fischinger, S., Kaur, D., Brody, R., Siddiqui, S. M., Leach, D., Brown, C., Klevens, R. M., Madoff, L., Comeau, A. M.
10.1101/2021.10.29.21265678 — Posted: 2021-10-30
The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
Chatterjee, M., Huang, L. Z. X., Wang, C., Mykytyn, A. Z., Westendorp, B., Wubbolts, R. W., Bosch, B. J., Haagmans, B., Putten, J. P. M. v., Strijbis, K.
10.1101/2021.10.29.466408 — Posted: 2021-10-29 Discussion: Offsite
Analyzing SARS CoV-2 Patient Data Using Quantum Supervised Machine Learning
Yu, Z.
10.1101/2021.10.26.466019 — Posted: 2021-10-29
Identification of COVID-19 and COPD common key genes and pathways using a protein-protein interaction approach
Thambiraja, T. S., Karuppanan, K., Subramaniam, G., Kumar, S.
10.1101/2021.10.28.466298 — Posted: 2021-10-29
Efficacy of anti-microbial gel vapours against aerosolised coronavirus, bacteria, and fungi
Kalaiselvan, P., Yasir, M., Willcox, M. D. P., Vijay, A. K.
10.1101/2021.10.27.466182 — Posted: 2021-10-29
Camel nanobodies broadly neutralize SARS-CoV-2 variants
Hong, J., Kwon, H. J., Cachau, R., Chen, C. Z., Butay, K. J., Duan, Z., Li, D., Ren, H., Liang, T., Zhu, J., Dandey, V. P., Martin, N. P., Esposito, D., Ortega-Rodriguez, U., Xu, M., Borgnia, M. J., Xie, H., Ho, M.
10.1101/2021.10.27.465996 — Posted: 2021-10-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).